AKT1 and ovarian carcinoma: Another variant, COL11A1, activates PI3K/Akt and NFκB pathways to exert anti-apoptotic effects that are associated with chemoresistance [118]; high expression of this variant was significantly associated with platinum resistance and clinical outcome in ovarian cancer (Supplementary Table S1).